Pfizer (PFE) Stock Forecast for 2024–2028. Sell or Buy Prediction

Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Pfizer (PFE) Stock Forecast for 2024–2028. Sell or Buy?

Updated: June 24, 2024 (01:08)

Sector: Healthcare

The share price of Pfizer Inc. (PFE) now

Latest session on the 21st of June for
Pfizer Inc. is negative
Trading Volume: 52561555
Open: 27.77 /  High: 27.89 /  Low: 27.56
What analysts predict: $31.46
52-week High/Low: $35.8 / $24.83

50/200 Day Moving Average: $27.56 / $29.01

This figure corresponds to the Average Price over the previous 50/200 days. For Pfizer stocks, the 50-day moving average is the support level today.

For Pfizer stocks, the 200-day moving average is the resistance level today.

Are you interested in Pfizer Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Pfizer stock price in 2024, 2025, 2026, 2027, 2028. How much will one Pfizer share be worth in 2024 - 2028?

When should I take profit in Pfizer stock? When should I record a loss on Pfizer stock? What are analysts' forecasts for Pfizer stock? What is the future of Pfizer stock? We forecast Pfizer stock performance using neural networks based on historical data on Pfizer stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Pfizer stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Pfizer shares. This happens once a day.

Historical and forecast chart of Pfizer stock

The chart below shows the historical price of Pfizer stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Pfizer stock price can be found in the table below.

Long-term forecasts by years.

PFE Stock Forecast: Navigating the Waves of Change

Trend: Strong Bullish
Jun 18, 2024

The Pfizer (PFE) stock forecast is looking brighter, buoyed by a combination of factors that analysts and investors alike should keenly watch. At the forefront of influencing changes in the PFE stock rates are Pfizer's impressive Q1 results, highlighting strong performances in non-COVID products and successful cost-saving measures. Additionally, the seamless transition of Paxlovid into the commercial market spells a promising venue for revenue growth, potentially making the PFE stock price target more attractive.

Unlocking the Potential: Analyzing PFE's Growth Trajectory

To make the most accurate predictions regarding the PFE company's stock price, analysts are keeping an eye on several critical areas. The valuation and growth opportunities presented by Pfizer, coupled with positive Wall Street analyst sentiment, signal an undervalued stock ripe for investment. Price targets have seen an uptick, reflecting a robust confidence in Pfizer's market position and its ability to capitalize on new growth avenues.

However, it's not all smooth sailing. Potential risks such as patent expirations and regulatory hurdles remain on the horizon, underscoring the need for a nuanced analysis. By weighing these factors against Pfizer's history of overcoming similar challenges, analysts can gain a clearer perspective on whether PFE stock is a buy or sell. Keeping a close eye on these developments will help forecast whether PFE stock will go up, making it a critical strategy for anyone looking to invest in Pfizer stock.

  • Q1 Results and Paxlovid's Market Success
  • Valuation and Untapped Growth Opportunities
  • Analyst Sentiment and Price Targets Adjustments
  • Risk Assessment and Strategic Adaptability

In summary, understanding the intricate dance between opportunity and challenge is key to making informed predictions about Pfizer stock price forecast. As the landscape evolves, so too will the strategies for navigating PFE stock's potential highs and lows.

Review the original Analysis
About author

Pfizer Stock Forecast: A Look Ahead at PFE's Promising Future

Trend: Bullish
Jun 13, 2024

As analysts keenly observe the bustling dynamics within Pfizer (PFE), a few pivotal factors stand out, poised to shape the trajectory of PFE's stock price. At the forefront, the commercial business's performance emerges as a beacon of potential, with the first quarter surpassing expectations and signaling a robust return to growth. This element alone could be a linchpin for the PFE stock forecast, as sustained revenue and EPS growth are classic harbingers of rising stock prices.

Navigating Through Pfizer's Opportunities and Challenges

Another highly anticipated event is the update on Pfizer's obesity pipeline, particularly danuglipron, which is on the cusp of possibly reshaping investor perspectives. Should this treatment demonstrate efficacy and tolerability improvements, the ripple effect on the PFE stock price target could be significant, making it a key factor for analysts to monitor. Moreover, the introduction of Andrew Baum as the new Chief Strategy and Innovation Officer introduces a wildcard; his influence on Pfizer's strategic decisions could be pivotal, potentially offering fresh opportunities for growth.

On the flip side, Pfizer's hefty debt burden, consequent of the Seagen acquisition, presents a challenge. However, effective de-leveraging through cash flows and asset sales could mitigate concerns, enhancing the PFE stock buy or sell debate. Analysts will need to weigh these factors carefully, integrating the dynamics between Pfizer's commercial success, pipeline developments, strategic leadership changes, and fiscal health to forecast PFE's stock rates accurately.

  • Performance of the commercial business
  • Obesity pipeline update
  • Impact of the new Chief Strategy and Innovation Officer
  • Debt burden and de-leveraging efforts

Predicting the direction of PFE stock requires a nuanced understanding of these elements. For those wondering, "Will PFE stock go up?" the answer lies in how effectively Pfizer navigates its current opportunities and challenges. With an outlook characterized by hope and strategic maneuvers, Pfizer's narrative in the stock market is one of cautious optimism, making it a compelling case for investors and analysts alike.

Review the original Analysis
About author

Rising Cancer Rates & Strategic Acquisitions: A Forecast for Pfizer's Stock Performance

Trend: Neutral
Jun 07, 2024

When evaluating the future performance of PFE's stocks, understanding the company's strategic moves and the global healthcare landscape is crucial. Analysts keen on making precise PFE stock forecasts closely monitor several pivotal factors that signal change. Foremost among these is the mounting global incidence of cancer, which underpins a surge in demand for innovative treatments. Pfizer, with its enhanced focus on oncology through the recent acquisitions of Seagen and Trillium Therapeutics, is poised to capitalize on this upward trend. The PFE stock forecast gains bullish tones from these strategic moves, highlighting the importance of these acquisitions in bolstering Pfizer's oncology portfolio.

Investor Attention on Financial Health & Legal Landscapes

Advances in Pfizer's stock, or decisions on whether PFE stock is a buy or sell, also hinge on its financial outlook and R&D commitments. Analysts draw optimism from Pfizer's decision to ramp up its R&D investment to $2.5 billion, underpinning an aggressive approach toward innovation and new drug development. However, shadows loom large in the form of legal challenges surrounding the COVID-19 vaccine's efficacy and potential side effects linked to mRNA technology. These factors introduce uncertainty, suggesting that the question of "will PFE stock go up" might have complex answers. Thus, in plotting the PFE stock price target, analysts weave these elements into their predictions, aiming to capture the multifaceted drivers of stock performance.

The interplay of Pfizer's robust response to growing cancer rates, strategic acquisitions, and a fortified R&D budget with the lurking uncertainties of legal challenges presents a complex but invigorating scenario for investors. Balancing these factors with an eye on the Pfizer stock forecast and pricing trends, savvy analysts can navigate the uncertainties and opportunities that lie ahead for Pfizer's market valuation.

Review the original Analysis
About author

The Bright Future of PFE Stocks: An Unfolding Opportunity

In the world of high-stakes investing, few opportunities are as compelling as the case of Pfizer Inc. (NYSE:PFE). This pharmaceutical giant, standing on the threshold of its 176th year, has experienced a roller coaster in the stock market, touching a decade-low low of $26.93 per share. To understand the PFE stock forecast, it is crucial to investigate the events and factors poised to influence its performance.

The capability to predict PFE stock rates with high accuracy hinges significantly on analyzing the company’s strong fundamentals and upcoming market dynamics. Recently, the valuation of Pfizer has reached a depressed level, essentially providing a lucrative buying opportunity. Despite facing a decline in COVID-19 related product sales, Pfizer reported a commendable 7% operating sales growth in 2023, propelled by new product launches and the consistent growth of existing ones.

Factors Influencing PFE Stock Performance

Looking ahead, several core elements will play pivotal roles in shaping Pfizer’s stock trajectory. Firstly, the heavy influx of COVID-19 related revenue has bolstered Pfizer’s financial position, rendering the acquisition of Seagen—a leader in antibody-drug conjugate technology—a strategic masterstroke. This move positions Pfizer ahead in a competitive race within the pharma industry.

Moreover, while some of Pfizer’s key drugs are on the verge of hitting a patent cliff, the company’s robust and diverse pipeline promises not just to offset, but potentially eclipse, any potential shortfalls. Given these dynamics, forecasting a substantial upside for PFE stock seems not just optimistic but grounded in tangible facts and figures.

In conclusion, when contemplating the PFE stock buy or sell dilemma, it’s imperative to consider the projected EPS growth, the anticipated rise in EBITDA margins, and the transformative potential of Pfizer’s product pipeline. With an attractive dividend yield forecast of 6.19% for FY2024, the question isn’t so much ‘will PFE stock go up?’ but rather, ‘how high?’ As such, the PFE stock price target points towards an optimistic upward trend, making PFE stock an attractive proposition for both investors and analysts alike.

Pfizer Inc. stands tall as one of the global giants in the pharmaceutical industry, hailing from the United States. This powerhouse is behind a suite of well-known medications that have become household names. They’ve got Lipitor to keep cholesterol in check, Lyrica for nerve and muscle pain relief, Diflucan as an antifungal go-to, and Zithromax for bacterial infections.

There’s also the famed blue pill, Viagra, giving hope to those grappling with erectile dysfunction, while Celebrex battles arthritis and other forms of pain. Sermion comes to the aid of those with cognitive issues, Dostinex addresses hormonal imbalances, and Champix lends a hand to those determined to quit smoking.

Pfizer daily forecast for a month

Date Target Pes. Opt. Vol., %
Jun 25 28.61 28.32 28.88 2.00
Jun 26 28.20 27.63 28.60 3.52
Jun 27 28.26 27.97 28.87 3.21
Jun 28 28.07 27.50 28.64 4.17
Jun 29 27.96 27.66 28.51 3.09
Jun 30 28.28 28.06 28.54 1.72
Jul 01 28.46 28.14 29.12 3.46
Jul 02 28.16 27.75 28.64 3.20
Jul 03 27.97 27.34 28.18 3.07
Jul 04 28.26 27.66 28.71 3.80
Jul 05 28.03 27.65 28.28 2.28
Jul 06 27.98 27.40 28.53 4.14
Jul 07 27.97 27.30 28.27 3.57
Jul 08 28.37 27.94 29.02 3.87
Jul 09 29.09 28.67 29.72 3.65
Jul 10 28.96 28.73 29.64 3.17
Jul 11 28.65 28.16 29.20 3.66
Jul 12 28.91 28.72 29.32 2.08
Jul 13 28.40 27.72 28.91 4.30
Jul 14 28.36 27.80 28.85 3.79
Jul 15 28.14 27.90 28.33 1.54
Jul 16 27.49 27.21 27.97 2.82
Jul 17 27.30 26.79 27.71 3.46
Jul 18 28.11 27.64 28.67 3.75
Jul 19 27.96 27.33 28.50 4.30
Jul 20 28.14 27.57 28.54 3.52
Jul 21 28.12 27.52 28.78 4.60
Jul 22 28.01 27.77 28.40 2.27
Jul 23 28.11 27.54 28.57 3.74
Jul 24 27.47 27.28 28.06 2.84

Pfizer Daily Price Targets

Pfizer Stock Forecast 06-25-2024.

Forecast target price for 06-25-2024: $28.61.
Positive dynamics for Pfizer shares will prevail with possible volatility of 1.961%.
Pessimistic target level: 28.32
Optimistic target level: 28.88

Pfizer Stock Forecast 06-26-2024.

Forecast target price for 06-26-2024: $28.20.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.401%.
Pessimistic target level: 27.63
Optimistic target level: 28.60

Pfizer Stock Forecast 06-27-2024.

Forecast target price for 06-27-2024: $28.26.
Positive dynamics for Pfizer shares will prevail with possible volatility of 3.113%.
Pessimistic target level: 27.97
Optimistic target level: 28.87

Pfizer Stock Forecast 06-28-2024.

Forecast target price for 06-28-2024: $28.07.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.999%.
Pessimistic target level: 27.50
Optimistic target level: 28.64

Pfizer Stock Forecast 06-29-2024.

Forecast target price for 06-29-2024: $27.96.
Negative dynamics for Pfizer shares will prevail with possible volatility of 3.001%.
Pessimistic target level: 27.66
Optimistic target level: 28.51

Pfizer Stock Forecast 06-30-2024.

Forecast target price for 06-30-2024: $28.28.
Positive dynamics for Pfizer shares will prevail with possible volatility of 1.694%.
Pessimistic target level: 28.06
Optimistic target level: 28.54

PFE (PFE) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Jul. 28.69 27.22 30.39 10.45
Aug. 29.57 27.76 30.66 9.46
Sep. 30.87 29.81 32.90 9.37
Oct. 28.93 27.94 30.75 9.14
Nov. 27.26 26.45 28.56 7.39
Dec. 26.65 25.26 28.04 9.92

Pfizer forecast for this year

Pfizer Stock Prediction for Jul 2024

An uptrend is forecast for this month with an optimal target price of $28.6887. Pessimistic: $27.22. Optimistic: $30.39

Pfizer Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $29.5666. Pessimistic: $27.76. Optimistic: $30.66

Pfizer Stock Prediction for Sep 2024

An uptrend is forecast for this month with an optimal target price of $30.8705. Pessimistic: $29.81. Optimistic: $32.90

Pfizer Stock Prediction for Oct 2024

An downtrend is forecast for this month with an optimal target price of $28.9256. Pessimistic: $27.94. Optimistic: $30.75

Pfizer Stock Prediction for Nov 2024

An downtrend is forecast for this month with an optimal target price of $27.2595. Pessimistic: $26.45. Optimistic: $28.56

Pfizer Stock Prediction for Dec 2024

An downtrend is forecast for this month with an optimal target price of $26.6462. Pessimistic: $25.26. Optimistic: $28.04

Pfizer (PFE) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 26.98 26.45 28.20 6.20
Feb 26.71 25.71 28.40 9.48
Mar 26.64 25.04 28.49 12.12
Apr 28.73 27.05 29.97 9.75
May 26.76 25.34 27.97 9.39
Jun 27.56 26.79 28.18 4.93
Jul 26.37 24.97 27.44 9.00
Aug 26.32 24.99 28.10 11.04
Sep 25.30 24.82 26.55 6.52
Oct 26.08 24.62 27.84 11.55
Nov 25.04 24.05 26.31 8.57
Dec 26.10 24.36 26.95 9.59

Pfizer (PFE) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 25.59 24.99 26.51 5.73
Feb 26.02 24.67 27.17 9.22
Mar 24.24 23.04 25.55 9.82
Apr 23.85 23.08 24.37 5.29
May 22.18 20.74 23.29 10.97
Jun 21.52 20.08 22.93 12.41
Jul 21.81 21.16 23.01 8.02
Aug 21.95 21.18 22.74 6.86
Sep 22.50 21.14 24.08 12.19
Oct 21.91 20.81 22.60 7.94
Nov 20.37 19.16 21.84 12.26
Dec 20.08 19.01 20.75 8.36

Pfizer (PFE) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 18.69 18.07 19.06 5.21
Feb 19.36 18.54 20.55 9.75
Mar 19.78 18.60 20.56 9.52
Apr 20.35 19.10 21.47 11.01
May 19.45 18.24 20.64 11.62
Jun 19.52 18.33 20.59 11.01
Jul 19.07 18.41 20.06 8.21
Aug 18.52 17.93 19.78 9.35
Sep 19.67 18.73 20.94 10.57
Oct 18.48 17.18 19.13 10.17
Nov 17.30 16.94 18.39 7.87
Dec 17.11 16.45 18.25 9.87

Pfizer (PFE) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 16.90 15.89 17.60 9.68
Feb 18.16 17.67 18.96 6.81
Mar 17.49 17.16 18.18 5.63
Apr 17.05 16.22 18.06 10.19
May 18.17 17.24 19.20 10.22
Jun 18.12 17.78 18.45 3.62
Jul 17.94 16.94 18.84 10.11
Aug 19.33 18.60 19.73 5.73
Sep 18.84 18.11 19.37 6.48
Oct 18.76 18.08 19.74 8.38
Nov 18.28 17.91 19.16 6.53
Dec 17.72 16.45 18.75 12.25

Pfizer information and performance

Pfizer Address


Market Capitalization: 156 794 552 000 $

Market capitalization of the Pfizer Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of PFE shares in the company outstanding by the market price of one share.

EBITDA: 9 621 000 000 $

EBITDA of Pfizer is earnings before interest, income tax and depreciation of assets.

PE Ratio: None

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 0.256

Price/earnings to growth

DPS: 1.65

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0606

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: -0.05

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: -0.434
Quarterly Revenue Growth YOY: -0.195
Trailing PE: -

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 11.67

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 3.498

Enterprise Value (EV) /Revenue

EV To EBITDA: 21.41

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 5666590000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Pfizer (PFE) stock dividend

Pfizer last paid dividends on 05/09/2024. The next scheduled payment will be on 06/14/2024. The amount of dividends is $1.65 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.

Related stocks from Healthcare sector


All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.